CN114042132A - 锦灯笼宿萼醇提物在制备糖尿病药物中的应用 - Google Patents
锦灯笼宿萼醇提物在制备糖尿病药物中的应用 Download PDFInfo
- Publication number
- CN114042132A CN114042132A CN202111610617.1A CN202111610617A CN114042132A CN 114042132 A CN114042132 A CN 114042132A CN 202111610617 A CN202111610617 A CN 202111610617A CN 114042132 A CN114042132 A CN 114042132A
- Authority
- CN
- China
- Prior art keywords
- parts
- alcohol extract
- powder
- calyx seu
- calyx
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001164374 Calyx Species 0.000 title claims abstract description 34
- 244000064622 Physalis edulis Species 0.000 title claims abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 239000000284 extract Substances 0.000 title claims abstract description 21
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 37
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 23
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 23
- 235000008434 ginseng Nutrition 0.000 claims abstract description 23
- 238000003756 stirring Methods 0.000 claims abstract description 23
- 238000001914 filtration Methods 0.000 claims abstract description 16
- 241000241413 Propolis Species 0.000 claims abstract description 12
- 229940069949 propolis Drugs 0.000 claims abstract description 12
- 244000197580 Poria cocos Species 0.000 claims abstract description 9
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims abstract description 7
- 230000002085 persistent effect Effects 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 241000572565 Alpinia oxyphylla Species 0.000 claims abstract description 4
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 4
- 241000208340 Araliaceae Species 0.000 claims description 22
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 19
- 238000000227 grinding Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 14
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 14
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 14
- 235000013399 edible fruits Nutrition 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 10
- 244000241838 Lycium barbarum Species 0.000 claims description 8
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 8
- 235000015468 Lycium chinense Nutrition 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 6
- 235000000340 Solanum pseudocapsicum Nutrition 0.000 claims description 3
- 240000004482 Withania somnifera Species 0.000 claims description 3
- 235000001978 Withania somnifera Nutrition 0.000 claims description 3
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000011505 plaster Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 4
- 102000004877 Insulin Human genes 0.000 abstract description 3
- 108090001061 Insulin Proteins 0.000 abstract description 3
- 229940125396 insulin Drugs 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 abstract description 2
- 241000132012 Atractylodes Species 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 235000002226 Ranunculus ficaria Nutrition 0.000 description 5
- 241001530126 Scrophularia Species 0.000 description 5
- 230000006378 damage Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Diabetes (AREA)
- Insects & Arthropods (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Animal Husbandry (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了锦灯笼宿萼醇提物在制备糖尿病药物中的应用，包括如下步骤：（一）其组份按重量份数包括如下成分：锦灯笼宿萼醇提液1‑3份、玄参15‑20份、益智仁12‑22份、人参5‑8份、枸杞子25‑40份、蜂胶8‑10份、乌术粉6‑12份、茯苓7‑15份、怀山药8‑10份；（二）制备方法：S1、首先将玄参、益智仁和茯苓分别进行熬制出汁，并进行收集；S2、将上述步骤熬制的药汁进行过滤，然后加入乌术粉和枸杞子进行搅拌均匀。通过采用本发明制备的降糖膏，能够有效的降低使用者的血糖量，并且能够促进胰岛素的分泌和体内脂肪代谢，更好的保证使用者的身体健康，并且本发明采用中草药，副作用小，利用开水冲服即可，简单方便。
Description
技术领域
本发明涉及保健品技术领域，具体为锦灯笼宿萼醇提物在制备糖尿病药物中的应用。
背景技术
糖尿病是一组因胰岛素绝对或相对分泌不足和胰岛素利用障碍引起的碳水化合物、蛋白质、脂肪代谢紊乱性疾病，以高血糖为主要标志。它主要包括1型糖尿病和2型糖尿病。糖尿病在临床上典型的症状表现为“三多一少”，即多饮、多尿、多食和体重下降，以及血糖高、尿液中含有葡萄糖等。若糖尿病的病程过久则会引起多系统损害，导致眼、肾、神经、心脏、血管等组织器官的慢性进行性病变、功能减退及衰竭，病情严重或应激时可引起急性严重代谢紊乱。糖尿病是一种严重的内分泌疾病，其对人体健康的危害仅次于肿瘤和脑血管疾病。随着人们生活水平质量的提高以及对生活饮食习惯的不重视，糖尿病的发病率也在逐年上升。中药因其治疗糖尿病的副作用较小，所以近年来成为了学者们的研究热点。
锦灯笼中的化学成分具有降血糖的活性，所以对锦灯笼降血糖作用有效成分的研究越来越深入。根据前人的药理研究，锦灯笼中的甾体类成分与多糖类成分能够显著地降低血糖并减少患者摄水量。此外，阿魏酸和绿原酸也可以降低血糖，促进胰岛素的分泌和体内脂肪代谢。所以在临床应用中，锦灯笼也可通过配伍其它药物组成复方对糖尿病进行治疗。
发明内容
本发明的目的在于提供锦灯笼宿萼醇提物在制备糖尿病药物中的应用，具备降糖的优点，解决了上述背景提出的问题。
为实现上述目的，本发明提供如下技术方案：锦灯笼宿萼醇提物在制备糖尿病药物中的应用，包括如下步骤：
（一）其组份按重量份数包括如下成分：
锦灯笼宿萼醇提液 1-3份
玄参 15-20份
益智仁 12-22份
人参 5-8份
枸杞子 25-40份
蜂胶 8-10份
乌术粉 6-12份
茯苓 7-15份
怀山药 8-10份；
（二）制备方法：
S1、首先将玄参、益智仁和茯苓分别进行熬制出汁，并进行收集；
S2、将上述步骤熬制的药汁进行过滤，然后加入乌术粉和枸杞子进行搅拌均匀；
S3、将人参进行烘干，研磨成粉，然后将怀山药研磨成粉末，然后加入上述步骤的混合物中；
S4、将上述步骤的混合物中加入锦灯笼宿萼醇提液和蜂胶进行搅拌成膏状物，然后进行封罐，然后进行低温消毒；
S5、使用时，取出适量膏药，然后开水冲服即可。
优选的，所述步骤一中在熬制的时候，三碗水熬成一碗水，并在熬制之前对药材进行煎服。
优选的，所述步骤二中在对药汁进行过滤的时候利用离心机对药汁进行离心过滤，在过滤之前需进行初步的过滤。
优选的，所述步骤三中在对人参烘干的时候采用低温烘干，怀山药烘干时采用高温烘干。
优选的，所述步骤四中在搅拌的时候温度控制在40-60℃，且搅拌速率控制在800-1000r/min。
与现有技术相比，本发明的有益效果如下：
通过采用本发明制备的降糖膏，能够有效的降低使用者的血糖量，并且能够促进胰岛素的分泌和体内脂肪代谢，更好的保证使用者的身体健康，并且本发明采用中草药，副作用小，利用开水冲服即可，简单方便。
具体实施方式
下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
本发明提供一种技术方案：
锦灯笼宿萼醇提物在制备糖尿病药物中的应用，包括如下步骤：
（一）其组份按重量份数包括如下成分：
锦灯笼宿萼醇提液 1-3份
玄参 15-20份
益智仁 12-22份
人参 5-8份
枸杞子 25-40份
蜂胶 8-10份
乌术粉 6-12份
茯苓 7-15份
怀山药 8-10份；
（二）制备方法：
S1、首先将玄参、益智仁和茯苓分别进行熬制出汁，并进行收集；
S2、将上述步骤熬制的药汁进行过滤，然后加入乌术粉和枸杞子进行搅拌均匀；
S3、将人参进行烘干，研磨成粉，然后将怀山药研磨成粉末，然后加入上述步骤的混合物中；
S4、将上述步骤的混合物中加入锦灯笼宿萼醇提液和蜂胶进行搅拌成膏状物，然后进行封罐，然后进行低温消毒；
S5、使用时，取出适量膏药，然后开水冲服即可。
实施例一：
首先将玄参、益智仁和茯苓分别进行熬制出汁，并进行收集，然后将上述步骤熬制的药汁进行过滤，然后加入乌术粉和枸杞子进行搅拌均匀，然后将人参进行烘干，研磨成粉，然后将怀山药研磨成粉末，然后加入上述步骤的混合物中，最后将上述步骤的混合物中加入锦灯笼宿萼醇提液和蜂胶进行搅拌成膏状物，然后进行封罐，然后进行低温消毒，使用时，取出适量膏药，然后开水冲服即可。
实施例二：
在实施例一中，再加上下述工序：
步骤一中在熬制的时候，三碗水熬成一碗水，并在熬制之前对药材进行煎服。
首先将玄参、益智仁和茯苓分别进行熬制出汁，并进行收集，然后将上述步骤熬制的药汁进行过滤，然后加入乌术粉和枸杞子进行搅拌均匀，然后将人参进行烘干，研磨成粉，然后将怀山药研磨成粉末，然后加入上述步骤的混合物中，最后将上述步骤的混合物中加入锦灯笼宿萼醇提液和蜂胶进行搅拌成膏状物，然后进行封罐，然后进行低温消毒，使用时，取出适量膏药，然后开水冲服即可。
实施例三：
在实施例二中，再加上下述工序：
步骤二中在对药汁进行过滤的时候利用离心机对药汁进行离心过滤，在过滤之前需进行初步的过滤。
首先将玄参、益智仁和茯苓分别进行熬制出汁，并进行收集，然后将上述步骤熬制的药汁进行过滤，然后加入乌术粉和枸杞子进行搅拌均匀，然后将人参进行烘干，研磨成粉，然后将怀山药研磨成粉末，然后加入上述步骤的混合物中，最后将上述步骤的混合物中加入锦灯笼宿萼醇提液和蜂胶进行搅拌成膏状物，然后进行封罐，然后进行低温消毒，使用时，取出适量膏药，然后开水冲服即可。
实施例四：
在实施例三中，再加上下述工序：
步骤三中在对人参烘干的时候采用低温烘干，怀山药烘干时采用高温烘干。
首先将玄参、益智仁和茯苓分别进行熬制出汁，并进行收集，然后将上述步骤熬制的药汁进行过滤，然后加入乌术粉和枸杞子进行搅拌均匀，然后将人参进行烘干，研磨成粉，然后将怀山药研磨成粉末，然后加入上述步骤的混合物中，最后将上述步骤的混合物中加入锦灯笼宿萼醇提液和蜂胶进行搅拌成膏状物，然后进行封罐，然后进行低温消毒，使用时，取出适量膏药，然后开水冲服即可。
实施例五：
在实施例四中，再加上下述工序：
步骤四中在搅拌的时候温度控制在40-60℃，且搅拌速率控制在800-1000r/min。
首先将玄参、益智仁和茯苓分别进行熬制出汁，并进行收集，然后将上述步骤熬制的药汁进行过滤，然后加入乌术粉和枸杞子进行搅拌均匀，然后将人参进行烘干，研磨成粉，然后将怀山药研磨成粉末，然后加入上述步骤的混合物中，最后将上述步骤的混合物中加入锦灯笼宿萼醇提液和蜂胶进行搅拌成膏状物，然后进行封罐，然后进行低温消毒，使用时，取出适量膏药，然后开水冲服即可。
尽管已经示出和描述了本发明的实施例，对于本领域的普通技术人员而言，可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型，本发明的范围由所附权利要求及其等同物限定。
Claims (5)
1.锦灯笼宿萼醇提物在制备糖尿病药物中的应用，其特征在于：包括如下步骤：
（一）其组份按重量份数包括如下成分：
锦灯笼宿萼醇提液 1-3份
玄参 15-20份
益智仁 12-22份
人参 5-8份
枸杞子 25-40份
蜂胶 8-10份
乌术粉 6-12份
茯苓 7-15份
怀山药 8-10份；
（二）制备方法：
S1、首先将玄参、益智仁和茯苓分别进行熬制出汁，并进行收集；
S2、将上述步骤熬制的药汁进行过滤，然后加入乌术粉和枸杞子进行搅拌均匀；
S3、将人参进行烘干，研磨成粉，然后将怀山药研磨成粉末，然后加入上述步骤的混合物中；
S4、将上述步骤的混合物中加入锦灯笼宿萼醇提液和蜂胶进行搅拌成膏状物，然后进行封罐，然后进行低温消毒；
S5、使用时，取出适量膏药，然后开水冲服即可。
2.根据权利要求1所述的锦灯笼宿萼醇提物在制备糖尿病药物中的应用，其特征在于：所述步骤一中在熬制的时候，三碗水熬成一碗水，并在熬制之前对药材进行煎服。
3.根据权利要求1所述的锦灯笼宿萼醇提物在制备糖尿病药物中的应用，其特征在于：所述步骤二中在对药汁进行过滤的时候利用离心机对药汁进行离心过滤，在过滤之前需进行初步的过滤。
4.根据权利要求1所述的锦灯笼宿萼醇提物在制备糖尿病药物中的应用，其特征在于：所述步骤三中在对人参烘干的时候采用低温烘干，怀山药烘干时采用高温烘干。
5.根据权利要求1所述的锦灯笼宿萼醇提物在制备糖尿病药物中的应用，其特征在于：所述步骤四中在搅拌的时候温度控制在40-60℃，且搅拌速率控制在800-1000r/min。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111610617.1A CN114042132A (zh) | 2021-12-27 | 2021-12-27 | 锦灯笼宿萼醇提物在制备糖尿病药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111610617.1A CN114042132A (zh) | 2021-12-27 | 2021-12-27 | 锦灯笼宿萼醇提物在制备糖尿病药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114042132A true CN114042132A (zh) | 2022-02-15 |
Family
ID=80213337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111610617.1A Pending CN114042132A (zh) | 2021-12-27 | 2021-12-27 | 锦灯笼宿萼醇提物在制备糖尿病药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114042132A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115381887A (zh) * | 2022-08-03 | 2022-11-25 | 山东省农业科学院家禽研究所（山东省无特定病原鸡研究中心） | 锦灯笼在缓解鸡急性热应激损伤中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113017092A (zh) * | 2021-04-01 | 2021-06-25 | 吉林省特医食品生物科技有限公司 | 一种调节血糖的发酵型小分子肽混合液及其制备方法和应用 |
-
2021
- 2021-12-27 CN CN202111610617.1A patent/CN114042132A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113017092A (zh) * | 2021-04-01 | 2021-06-25 | 吉林省特医食品生物科技有限公司 | 一种调节血糖的发酵型小分子肽混合液及其制备方法和应用 |
Non-Patent Citations (1)
| Title |
|---|
| 徐英: "降血糖的草药有哪些", 《HTTPS://M.BAIDU.COM/BH/M/DETAIL/QR_16591590837215957734》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115381887A (zh) * | 2022-08-03 | 2022-11-25 | 山东省农业科学院家禽研究所（山东省无特定病原鸡研究中心） | 锦灯笼在缓解鸡急性热应激损伤中的应用 |
| CN115381887B (zh) * | 2022-08-03 | 2023-05-26 | 山东省农业科学院家禽研究所（山东省无特定病原鸡研究中心） | 锦灯笼在缓解鸡急性热应激损伤中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104431064A (zh) | 一种降糖茶及其制备方法 | |
| CN104082672A (zh) | 一种具有降血糖功效的养生粥及其制作方法 | |
| CN108524673A (zh) | 一种中药组合物及其应用 | |
| CN108578544A (zh) | 一种具有降糖作用的中药组合物及其制备方法与应用 | |
| CN102885975B (zh) | 一种治疗糖尿病的中药组合物 | |
| CN104815166B (zh) | 一种治疗糖尿病的中药组合物及其制备和应用 | |
| CN106924374A (zh) | 一种组合物及其制备方法与在制备降血糖和/或降血脂的产品中的应用 | |
| CN114042132A (zh) | 锦灯笼宿萼醇提物在制备糖尿病药物中的应用 | |
| CN103721075B (zh) | 一种用于妇产科术后的中药及其制备方法 | |
| CN106362007A (zh) | 含有霍山石斛的具有降糖作用的中药组合物及其制备方法 | |
| CN102018852B (zh) | 参连消渴降糖胶囊及制作工艺 | |
| CN101336965B (zh) | 一种用于改善糖耐量、降低血糖的中成药及其制备方法 | |
| CN105145931A (zh) | 一种降糖茶及其加工方法 | |
| CN103550505A (zh) | 治疗气阴两虚型糖尿病的中药制剂 | |
| CN113826882A (zh) | 防治糖尿病的膳食营养补充剂及其制备工艺 | |
| CN111150065A (zh) | 沙棘水溶性提取物在抑制Tau蛋白磷酸化制剂中的应用 | |
| CN101744991B (zh) | 一种人参、麦冬、五味子的单独提取方法及其制剂 | |
| CN103989940A (zh) | 一种治疗糖尿病的中药组合物 | |
| CN101293059B (zh) | 一种治疗糖尿病的中药复方制剂 | |
| CN103238834A (zh) | 一种治疗皮肤瘙痒的组合物及其制备方法 | |
| CN104524359B (zh) | 一种中药组合物、其制备方法及应用 | |
| CN101401849B (zh) | 茶多酚中药复方在制备降血脂且降血糖的药物中的应用 | |
| CN114712458B (zh) | 一种用于治疗高血压病血管衰老的药物组合物及其制备方法、应用 | |
| CN100548338C (zh) | 一种治疗痛风的中药制剂 | |
| CN107753589B (zh) | 一种治疗糖尿病的中药组合物及其制备工艺 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220215 |
|
| RJ01 | Rejection of invention patent application after publication |